Pyramid Biosciences Expands Precision Oncology Pipeline
Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases, today announced the global licensing of the novel monopolar spindle1 (MPS1) called VRN-08 and a second undisclosed asset from Voronoi Inc., a South Korea-based biotechnology company the develops novel kinase inhibitors and target protein degraders. The milestone-based deal is worth up $846 million dollars (USD). Read more >>